Opinion|Videos|October 15, 2024
First-Line Luspatercept in LR-MDS: A Deep Dive Into the COMMANDS Trial and Clinical Implications in the Real-Life Practice Setting
Panelists discuss how luspatercept’s mechanism of action, its first-line indication for patients with lower-risk MDS with ring sideroblasts, and the results of the COMMANDS trial support its use as an effective alternative to traditional erythropoiesis-stimulating agents, potentially changing the treatment landscape for transfusion-dependent patients with MDS.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please describe the mechanism of luspatercept and luspatercept’s indication in the first-line setting
- Please summarize the COMMANDS trial (Della Porta MG, et al. Lancet Haematol, 2024).
- Please comment on the study design, pertinent patient characteristics, and primary/secondary end points.
- What are your impressions of the recently published full analysis of the COMMANDS trial?
- What are the clinical implications of this study?
- What are your impressions and interpretation of luspatercept’s impact on the various hematopoietic stem cell lineages (erythroid, neutrophil, platelet)? How do these data impact your day-to-day practice?
- Resource links: Luspatercept’s impact on erythroid, neutrophil, and platelet lineages. Garcia-Manero G, et al. EHA 2024. Abstract P780 & COMMANDS trial (Della Porta MG, et al. Lancet Haematol, 2024)
Advertisement
Related to this article
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
A 3-year, $225K award will focus on improving quality of life for patients living with long-term effects of cancer treatment.
China's NMPA accepted a supplemental application expanding toripalimab's perioperative NSCLC indication to stage II-III disease.
An updated HARMONi analysis showed a consistent OS benefit with ivonescimab plus chemotherapy in EGFR-mutated NSCLC.
Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
Sacituzumab govitecan produced an ORR of 35% in heavily pretreated platinum-resistant ovarian cancer in a phase 2 study.
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Sacituzumab Govitecan Yields Responses in Platinum-Resistant Ovarian Cancer
3
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
4
Dr Mardones on Giredestrant Plus Palbociclib in Estrogen Receptor+ Breast Cancer
5